ROSSARI Rossari Biotech Q2 FY26 results (Jul–Sep 2025) and concall
Rossari Biotech reported strong Q2 FY26 results with an 18% YoY revenue growth, primarily driven by healthy volume expansion across all core businesses and robust export performance. While the operating environment remained dynamic with subdued pricing and tariff pressures, the company successfully commissioned new capacities and continued investments in R&D. Profitability saw a slight dip in overall EBITDA margin to 12.3% due to investments and one-time expenses, but core B2B margins remained stable.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 368 | 427 | 366 | 420 |
| EBITDA | 50 | 52 | 44 | 50 |
| Net profit | 31 | 32 | 26 | 31 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
